First-quarter net sales of Lovenox ® were €583 million, down 26.5%, reflecting a generic competitor in the U.S. (U.S. sales were €222 million down 51.0%)($329 million US). Outside the U.S., sales reached €361 million (representing 61.9% of Lovenox sales) and grew by 5.4% driven by the Emerging Markets (+16.7% to €132 million).
Market Data 
Markets 
AI
